Jack Taunton, Ph.D.

  /  

Jack Taunton, Ph.D.

Jack Taunton has spent much of his career developing biochemical tools to illuminate cellular processes relevant to cancer and autoimmune diseases. His work designing covalent inhibitors that target protein kinases led to a drug candidate that’s now advancing through clinical trials. He also discovered a family of cyclic depsipeptides that represent a promising new class of oncology drugs. Jack earned his Ph.D. in chemistry from Harvard University and is a co-founder of Global Blood Therapeutics, Principia Biopharma and Kezar Life Sciences.

William Kaelin, Jr., M.D.

  /  

William Kaelin, Jr., M.D.

Bill Kaelin’s distinguished research career has focused on the proteins encoded by tumor suppressor genes and how mutations in those genes cause cancer. His work on the VHL protein delivered new insights into how cells respond to changes in oxygen levels – and motivated the successful clinical testing of VEGF inhibitors, which are now approved to treat kidney cancer. A professor at the Dana-Farber Cancer Institute and Harvard Medical School, Bill brings deep expertise in the regulation of oncoproteins to Cedilla. He also brings a unique cell-based assay that quickly screens cells to find upstream regulators that control the stability of proteins. Bill has won many top scientific honors, including the ASCO Science of Oncology Award, the Canada Gairdner International Award and the Albert Lasker Award for Basic Medical Research. He sits on the editorial board of numerous journals, including Cancer Cell, and has served on the National Cancer Institute’s Board of Scientific Advisors. Bill received his M.D. from Duke University

Matthew Jacobson, Ph.D.

  /  

Matthew Jacobson, Ph.D.

Matt Jacobson is a veteran researcher and entrepreneur with deep experience in both molecular biophysics and drug discovery. A professor at the University of California, San Francisco School of Pharmacy, Matt focuses on research including predicting protein function and regulation, creating new methods for computer-aided drug design and investigating new approaches to treating neurodegenerative diseases.  Matt, who earned his Ph.D. in physical chemistry from MIT, is also a co-founder of Circle Pharma, Relay Therapeutics and Global Blood Therapeutics. He serves on the scientific advisory board of Schrodinger LLC.

Steve Gygi, Ph.D.

  /  

Steve Gygi, Ph.D.

Steve Gygi brings a deep expertise in mass spectrometry and proteomics, with a particular focus on detecting and quantifying the changes that ensue after a protein is perturbed by an external event, such as pharmacological or pathological intervention. A professor of cell biology at Harvard Medical School, Steve specializes in developing technologies for rapid, sensitive and multifaceted analysis of proteins. His lab co-published a protein interaction network, the BioPlex, that includes more than 9,000 proteins. Steve received his Ph.D. in pharmacology and toxicology from the University of Utah.

Alan D’Andrea, M.D.

  /  

Alan D’Andrea, M.D.

Alan D’Andrea brings years of research insights into DNA repair pathways, oncoproteins and ubiquitin to Cedilla. A professor of radiation oncology at Harvard Medical School, Alan also serves as director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute. Alan’s research centers on the molecular signaling pathways that regulate the cellular response to DNA damage, with a particular focus on the pathogenesis of human chromosome instability and the identification of novel interacting proteins. Alan is a graduate of Harvard Medical School and a member of the National Academy of Science and the National Academy of Medicine.